| Aug 28 2015 |
What’s in a Name? That Which We Call a Biological Product… |
Sheppard, Mullin, Richter & Hampton LLP |
| Aug 28 2015 |
FDA’s Proposed Naming Convention for Biologics |
Foley & Lardner LLP |
| Aug 28 2015 |
Health Resources and Service Administration (HRSA) Issues Proposed “Omnibus Guidance” |
Epstein Becker & Green, P.C. |
| Aug 28 2015 |
Amgen Inc., et al. v. Sandoz, Inc.: Shall Means Shall . . . Unless It Doesn’t |
McDermott Will & Emery |
| Aug 27 2015 |
Food Standards of Identity Remain a Focus of FDA Regulatory Action |
Michael Best & Friedrich LLP |
| Aug 27 2015 |
Sixth Circuit Assesses Class Action Criteria in Digestive Drug Litigation |
Squire Patton Boggs (US) LLP |
| Aug 27 2015 |
Amgen And Apotex Do The Biosimilar Patent Dance |
Foley & Lardner LLP |
| Aug 26 2015 |
Kyle Bass Loses Round 1 Of IPR Attack Against Pharma/Biotech Patents |
Foley & Lardner LLP |
| Aug 26 2015 |
Trademarking: Capri Sun Says “Respect the Pouch” |
IMS Legal Strategies |
| Aug 26 2015 |
State Pharmaceutical Pricing Disclosure Laws: Old Story, New Refrain |
Mintz |
| Aug 26 2015 |
AmerisourceBergen Guest Post: Solutions to Overcome Reimbursement Challenges in Personalized Medicine |
Foley & Lardner LLP |
| Aug 26 2015 |
Litigation Fallout From All This Supply Chain Transparency Legislation (Or, These Things Have Teeth!) (Or, The Cycle of Misfortune) |
Squire Patton Boggs (US) LLP |
| Aug 25 2015 |
FDA Flunks Mylan’s India Facilities, Finds cGMP Violations |
Mahany Law |
| Aug 25 2015 |
PTAB Denies Institution Of Kyle Bass's Ampyra Patent Challenge |
Foley & Lardner LLP |
| Aug 24 2015 |
Protecting Diagnostic Innovation – Two Actor Infringement Liability |
Foley & Lardner LLP |
| Aug 21 2015 |
New Guide On Safety Assessments of NIAS in Food-Contact Materials Available from ILSI Europe |
Keller and Heckman LLP |
| Aug 21 2015 |
Off-Label Marketing and False Claims Act |
Mintz |
| Aug 21 2015 |
FDA Adds Three New Substances to Its Inventory of Effective FCS Notifications |
Keller and Heckman LLP |
| Aug 21 2015 |
Food Court Report: Consumer Claims Targeting Trans Fat In Instant Noodles Case Survive Motion To Dismiss |
Keller and Heckman LLP |
| Aug 20 2015 |
Italian Medicines Agency Makes Public Assessment Reports Available on its Website |
Covington & Burling LLP |
| Aug 20 2015 |
Federal Circuit Expands Direct Divided Infringement |
Foley & Lardner LLP |
| Aug 19 2015 |
Amarin Ruling Solidifies Off-Label Marketing Options but Raises Questions About False Claims Act Enforcement Action |
McDermott Will & Emery |
| Aug 18 2015 |
The Future of Pharmaceutical Supply Chains (Or, Unpacking the Drug Quality and Security Act) |
Squire Patton Boggs (US) LLP |
| Aug 18 2015 |
Sequenom Seeks Rehearing En Banc |
Foley & Lardner LLP |
| Aug 17 2015 |
First Amendment Protects Truthful Off-Label Speech by Drug Manufacturers |
Mintz |
| Aug 17 2015 |
Amgen v. Apotex – what is the outcome when biosimilar applicants actually dance? |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Aug 16 2015 |
Claims Unpatentable for Obviousness in Final Written Decision IPR2014-00402 - Butamax Advanced Biofuels v. Gevo |
Faegre Drinker |
| Aug 14 2015 |
U.S. v. Bayer Is Proof ─ Daubert Is Not Hard To Digest |
IMS Legal Strategies |
| Aug 13 2015 |
Telehealth / Remote Care 2.0: The Coming Disruption |
Epstein Becker & Green, P.C. |
| Aug 13 2015 |
New York Federal Court Authorizes Pharmaceutical Firm to Engage in Off-label Promotion Using Certain Specific Information and Statements Alert |
Barnes & Thornburg LLP |
| Aug 13 2015 |
This Week’s Health Care Update: Big Changes (Possibly) Ahead for Drug Manufacturers |
Mintz |
| Aug 13 2015 |
Value Of Prophetic Examples re: Lumigan Patent Claims |
Foley & Lardner LLP |
| Aug 12 2015 |
FDA Cites Drug Company for Kim Kardashian Endorsement |
Mintz |
| Aug 12 2015 |
OHIM: DETOX Is Not Descriptive For The Characteristics Of “Beers” |
Squire Patton Boggs (US) LLP |
| Aug 11 2015 |
Medtronic Covidien Settles More than 11,000 Claims |
Stark & Stark |
